| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Uniqure N.V. (QURE) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 10 sells. QURE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 150.4K | $6.96M | - | |
| Other | 133.2K | $6.17M | -5,237 | |
| CFO | 63.9K | $2.96M | - | |
| Dir | 53.3K | $2.47M | -10,000 | |
| Dir | 40.1K | $1.86M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2018 | Kapusta Matthew C64 | CEO, CFO, Managing Director | Sell | 39,169 | $21.72 | $850,750.68 | -8.2% | |
| Jan 29, 2018 | Van Deventer Sander | Chief Scientific Officer | Sell | 5,985 | $18.53 | $110,902.05 | -19.3% | |
| Jan 29, 2018 | Soteropoulos Paula75 | Director | Sell | 2,878 | $18.53 | $53,329.34 | -13.8% | |
| Jan 29, 2018 | Astley-Sparke Philip47 | Director | Sell | 6,540 | $18.53 | $121,186.20 | -18.8% | |
| Jan 29, 2018 | Kaye Jack53 | Director | Sell | 2,878 | $18.53 | $53,329.34 | -18.2% | |
| Jan 29, 2018 | Schaffer David86 | Director | Sell | 2,878 | $18.53 | $53,329.34 | -15.8% | |
| Jan 4, 2018 | Kapusta Matthew C64 | CEO, CFO, Managing Director | Sell | 21,690 | $19.87 | $431,069.23 | -4.6% | |
| Jan 3, 2018 | Klemt Christian58 | Chief Accounting Officer | Sell | 5,093 | $20.13 | $102,509.87 | -12.0% | |
| Jan 3, 2018 | Garen Jonathan | Chief Business Officer | Sell | 5,864 | $20.13 | $118,028.25 | -6.4% | |
| Jan 3, 2018 | Firuta Paul E | Chief Commercial Officer | Sell | 5,864 | $20.13 | $118,028.25 | -6.4% |